Compare CRMT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | TNXP |
|---|---|---|
| Founded | 1981 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.5M | 231.3M |
| IPO Year | N/A | N/A |
| Metric | CRMT | TNXP |
|---|---|---|
| Price | $26.69 | $17.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $45.00 | ★ $70.00 |
| AVG Volume (30 Days) | 219.5K | ★ 638.0K |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,381,482,000.00 | $10,299,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | $4.22 | $933.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.01 | N/A |
| 52 Week Low | $17.78 | $6.76 |
| 52 Week High | $62.72 | $72.00 |
| Indicator | CRMT | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 43.38 |
| Support Level | $24.00 | $17.71 |
| Resistance Level | $28.65 | $19.35 |
| Average True Range (ATR) | 2.04 | 1.34 |
| MACD | 0.32 | 0.04 |
| Stochastic Oscillator | 78.67 | 37.55 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.